Abstract: Treatment-resistant Depression (TRD) is the failure of pharmacological treatment, with or without psychotherapy or electroconvulsive therapy, in major depressive disorder patients. Over the past years, various trials of Deep Brain Stimulation (DBS) in TRD patients have been performed. By means of a systematic Pubmed search, the reports on these trials were gathered and critically appraised. Even though the reported research methodology was flawed, the combined study outcomes (of a total of fifty patients, 58% (95% CI = [44.2%; 70.6%]) showed a response to treatment and 26% (95% CI = [15.8% ; 39.7]) were considered being in remission) are promising. Nonetheless, further research is required to evaluate the most beneficial stimulation areas in the brain, the stimulation parameters, and the possible long-term therapeutic and side-effects.
INTRODUCTION
Major depression is a mental illness characterized by an all-encompassing low mood, profound sadness, or anhedonia, which is the loss of interest or pleasure in what was before enjoyable and gratifying activities. In addition to the aforementioned symptoms, depression is often accompanied by a battery of other arduous symptoms such as sleep disturbances, changes in appetite, fatigue, feeling of worthlessness, executive dysfunction, psychomotor agitation/retardation and worst of all suicidal intentions [1] . Moreover, depressed patients are prone to a greater susceptibility to medical illnesses, which result in shorter lifeexpectancy. Furthermore, major depression patients may experience stigmatization in their social surrounding. This disease is a world-wide burden and has a life-prevalence of about 8-12% [2] [3] [4] with females seemingly being affected twice as often as males [5] . Many patients can be helped with psychotherapy, antidepressant medication, electroconvulsive therapy, or a combination of the aforementioned. However, 15-33% of all patients do not respond adequately to the aforesaid treatments [6] . The term 'treatment-resistant depression' (TRD) was coined for this phenomenon. Table 1 gives an overview of a common classification of TRD. For the TRD patients, deep brain stimulation (DBS) has been proposed as a possible treatment.
DBS is a surgical treatment that utilizes a so called brain pacemaker; a device that sends electrical signals to specific areas of the brain through implanted electrodes. The mechanism of DBS is still not completely understood, though five general hypotheses exist: depolarization blockage, synaptic inhibition, synaptic depression, stimulation-induced modulation of pathologic network activity, and a combination of the aforementioned hypotheses [7] . Based on the idea that *Address correspondence to these authors at the Department of Neurosurgery, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands; Tel: 0031-43-3876052; Fax: 0031-43-3876038; E-mails: t.sarnecki@student.maastrichtuniversity.nl, y.temel@maastrichtuniversity.nl dysfunction in monoamine brain-circuits are the basis of the pathophysiology of depression, several structures have been proposed as potential stimulation sites [8] . This review has the intention to give a summation of the findings of the clinical studies on DBS and TRD that have been concluded thus far. 
MATERIAL AND METHODS
A Medline search (PubMed) was performed using the following 'Mesh' and free terms, and their combinations: 'Major Depressive Disorder', 'Depression', 'Treatmentresistant Depression', ' Deep Brain Stimulation', and 'DBS'. All 916 articles published before March 2010 were screened as available by their titles and abstracts. Clinical studies on deep brain stimulation that were carried out exclusively on unipolar depressed patients were included. Case studies [9] [10] [11] were excluded due to their high risk of publication bias. Reports on ethical issues concerning DBS were also ignored. Additionally, studies performed on obsessive-compulsive disorder or Parkinson's disease patients receiving DBS were excluded due to potential differences in pathophysiology [12] . Likewise, studies on epidural stimulation were not taken into account [13] . Conclusively, of the 916 articles, five clinical studies with a total of 50 patients were seen fit for inclusion and critically appraised ( Table 4 .
Only the results of the Hamilton Depression Rating Scale (HDRS) were used to evaluate and compare the effect of the treatment. This was done for two reasons: First, HDRS was often the only results presented quantitatively in the papers; secondly, HDRS is considered the gold standard in psychiatry for diagnosing major depressive disorder [16, 17] . A HDRS of 0-3 is considered not ill and a score above eight is established as mildly ill; the severity of the disease increases with the number. HDRS is a multiple-choice questionnaire performed by a clinician, the number stated after HDRS indicates how many items were used in the specific test. Here, and in most evaluated articles, a response to therapy is defined as a reduction of HDRS of more than half and remission is defined as a HDRS of lower or equal to eight. The confidence intervals were calculated using the adjusted Wald method.
RESULTS
Mayberg et al. [18] were the first to experiment with DBS in depressive patients in 2005. They performed DBS of the subgenual cingulate white matter in six TRD patients. Two of these patients showed a reduction of more than 50% in HDRS-24 within six months. Even more notable, two patients had a HDRS-24 lower than eight. However, the prevalence of side-effects was high; two patients had an infection on device implantation site, another patient had complaints of skin erosion. The reported methodology is acceptable. Downsides of the experiment are small sample-size and inclusion of a bipolar II patient. Aside from that, mere singleblindation on patient level increases the risk of reporter's bias. Another article (McNeely et al.) [19] stated that the same patient group showed no adverse changes in neuropsychological testings at 12 months, with the exception of slower motor speed. Depression ratings were not reevaluated in this report.
In 2008 Lozano et al. [20] reported on subcallosal cingulate gyrus DBS in twenty TRD patients. Of these 20 patients, six were already described by Mayberg et al. in 2005. In total, eleven patients showed a decrease in HDRS-17 of more than 50%, of which seven patients even achieved a score lower than eight of the HDRS-17. Complications included five wound infections, consequently, pacemakers needed to be removed in three patients; one peri-operative seizure and other, minor complications. Blindation to stimulation settings was performed only on patient level.
Schlaepfer et al. [21] implemented DBS of the nucleus accumbens in three TRD patients in 2007. One of these patients showed a reduction of more than 50% in HDRS-17. Alleviation of anhedonia was found in all patients. This report however was flawed by apparent methodological weaknesses: Sample size was extremely small and patients were not followed-up longer than five, eight and 22 weeks, respectively. Inclusion criteria were few and no exclusion criteria were stated. Moreover, no description of blindation methods was given.
Bewernick et al. [22] also evaluated DBS of the nucleus accumbens in ten TRD patients in 2010. It is not certain if the three patients of Schlaepfer et al. were part of the sample-size. Of these patients, five showed a reduction of at least 50% in HDRS-28. Two patients dropped out of the study before twenty months, one of them due to suicide after noncompliance by refusing any changes of parameter settings. The reason for drop-out of the other patient was not given. A long list of physical and psychological side-effects was reported, of which most were parameter setting dependent. An example is stimulation induced increase of anxiety, agitation and hypomania. Methodological weaknesses include no blindation and no reasons were given for loss to follow-up.
Malone et al. [23] performed DBS of the ventral capsule/ventral striatum in 15 TRD patients and described their findings in an article published in 2009. Larger leads than the standard leads were used in this study. Six subjects had a reduction in HDRS-24 of more than 50%; of these patients, three had a score lower than eight at six months. Four patients were lost to follow-up without any reasons given. Reported side-effects included pain at incision site, one lead fracture, and reversible, stimulation induced hypomania. Furthermore, in this study, blindation only occurred on patient level.
An update on the findings by Malone et al. [15] was published July 2010 and reported on the total outcome of 17 TRD patients, two more than in 2009. The focus of the article lies on summarizing the experiments done by Malone et al. thus far, with a minimum follow-up of the patients of 14 months. However, only the mean outcomes of the Montgomery-Åsberg Depression Rating Scale (MADRS), another widely used psychiatric diagnostic questionnaire for depression, were stated. Since HDRS and MADRS have been proven to correlate [24] , therefore, the equation (Table 3) by Heo et al. was used to convert the MADRS to HDRS-17. Of the 17 patients, twelve showed a response of more than 50% at last follow-up. Six of the twelve responding patients were considered being in remission. In addition to the above stated side-effects, infections, adverse cosmetic effects, frequent surgeries due to depleted batteries and stimulation induced but reversible acute adverse effects were reported.
DISCUSSION
Summarizing the findings of the fifty patients together, a staggering 58% (95% confidence interval (CI) = [44.2%; 70.6%]) of all patients showed a response. Of all patients, 26% (95% CI = [15.8% ; 39.7]) were even considered being in remission. Thus, the numbers implicate that the chances of improving depression with DBS are favorable, whilst the chance of a complete cure is slim. Positively, it seems as if the procedure causes no adverse neuropsychological effects besides slower motor speed [19] . However, sample-sizes for the different target areas are small and no long-term outcomes are available. Moreover, despite the fact that relapses of depressive symptoms had occurred in at least one patient, they weren't mentioned in the articles [25] . Henceforth, more research is needed to determine the most beneficial stimulation areas, including hypothetical target areas that haven't been evaluated by experiments yet, examples being the lateral habenula as seen in a case study [11] and stimulation of the ventral tegmental area that alleviated depressive behavior in rats [26] . Moreover, the most beneficial stimulation parameters, and the risks of DBS in TRD patients must be properly assessed. Although improbable, a possible placebo effect hasn't been ruled out entirely. What is more, comorbid psychiatric disorders of the patients were not taken into account. Evaluating response differences in patients with co-morbid psychiatric disorders are of particular interest, as can be seen in the clinical course of one included bipolar I patient that was reported to be very variable with episodes of stimulation induced hypomania [23] . It should be mentioned, as with all psychiatric diseases, that diagnosing major depressive disorder can be difficult. HDRS, the gold standard for depression, has been criticized in the past for having poor interrater and retest reliability [16] and content validity [16, 17] . Barring that, different item HDRSs used could lead to differences in scores. However, at least for the results of remission, these differences are certainly negligible. Lastly, it is noticeable that most researchers report conflicts of interest by accepting grants and funds from firms such as Medtronic. This, together with no blindation on an examiner level, increases the risk of a reporter's bias.
CONCLUSIONS
Although only a moderate percentage of patients gained relief, one must keep in mind that these were the patients in which standard therapy had failed them. Under this aspect, therefore, the results are indeed very promising. However, sample sizes were small and a lack of proper research methodology was apparent; as a consequence, the most beneficial stimulation areas, parameters and its side-effects are not yet determinable.
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